Will Regenerative Medicine Become 'Medicine for the Rich'? Taiwan Health Minister Responds

On March 20, the Social Welfare and Environmental Hygiene Committee of Taiwan’s Legislative Yuan reviewed the nation’s proposed dual regenerative medicine bills: the draft Regenerative Medicine Act and the draft Regenerative Medicinal Products Act. Minister of Health and Welfare Jhy-Wey Shieh stated that the government is preparing to incorporate regenerative medicine into the National Health Insurance (NHI) benefit framework, and is currently negotiating pricing with pharmaceutical and biotech manufacturers.

The Dilemma: Breakthrough Therapy vs. High Cost

Regenerative medicine (Regenerative Medicine) represents a transformative frontier in healthcare, utilizing autologous cells (autologous cells) or allogeneic cells (allogeneic cells) to repair damaged tissues and treat previously intractable conditions. While showing immense therapeutic promise for various complex diseases and cancers, its steep development and production costs have sparked parliamentary concerns that regenerative therapies could degenerate into “medicine exclusively for the wealthy,” remaining out of reach for average citizens.

To address affordability, Minister Shieh stated that the Ministry of Health and Welfare (MOHW) is exploring collaborative mechanisms with commercial health insurance providers alongside the public NHI system. Shieh emphasized that given Taiwan’s robust universal health coverage, the administration must determine the optimal model for reimbursement while engaging the Financial Supervisory Commission (FSC) and private insurers.

However, he conceded that domestic commercial insurance carriers tend to be conservative and typically demand extensive long-term clinical data—information that health authorities cannot readily provide at this nascent stage. While formal negotiations with commercial insurers have not yet begun, the ministry plans to coordinate tripartite discussions with the FSC and the insurance sector.

Conditional Reimbursement and Transparent Pricing Standards

Addressing recent inquiries on reimbursing novel cancer drugs under NHI, Shieh explained that medications anticipated for potential inclusion over the next two years must first submit formal applications. The NHI administration will evaluate financial impact, budgetary sustainability, and projected patient volume before granting coverage. Shieh also noted that health authorities are considering conditional or temporary reimbursement mechanisms—funding a new therapy for an initial trial window of 1 to 2 years, with the option to reduce or discontinue coverage if real-world efficacy falls short of expectations.

Once the dual regenerative medicine laws pass, permitting the use of allogeneic cells alongside autologous sources is expected to significantly reduce manufacturing and research costs. In response to lawmakers’ questions regarding price regulation, Minister Shieh noted that while medical pricing standards are legally designated to local municipalities under the Medical Care Act, local governments often face challenges calculating specialized biotech costs. Consequently, the central government will establish a standardized reference price ceiling to guide local health bureaus, ensuring that fees for regenerative treatments remain fair, transparent, and reasonable.